NCT04068597: Phase 1/2: Study to Evaluate CCS1477 in Haematological Malignancies - RRMM Myeloma
17th International Myeloma Workshop: September 12-15, 2019 Boston, MA
Dana-Farber's 2019 Multiple Myeloma Patient Symposium - | Current & Future Treatment
Nature Video: Decoding cancer immunology: Hunting hidden tumours
NCT04150965: Phase 1/2: Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT
Myeloma Canada: Patient Handbook - High-dose Therapy and Autologous Stem Cell Transplantation
What is Plasma Cell Leukemia? HealthTree University Myeloma
HealthTree University: What is a monoclonal protein (M-protein, M-spike) how is it detected?
NCT03909412: Phase 1: Carfilzomib Based Chemotherapy Mobilization for ASCT in Myeloma (CarMob)
NCCN Webinar : Know What Your Doctors Know: Multiple Myeloma - Part 1 to 11 and Q&A
NCT04108195: Phase 1b - Subcutaneous Dara With Bispecific T Cell Redirection Antibodies - TRIMM-2
NCT04035226 - Study of Real-life Current Standards of Care in Patients With RRMM with 3 prior lines
NCT03989414: Phase 1/2 - A Study of CC-92480 With Standard Treatments in Relapsed & New MM - MM-002
NCT03940833: Phase 1/2: Adoptive BCMA CAR-NK Cells - RRMM
NCT038282: Phase 1 - Dose Esc Study Belantamab mafodotin (GSK2857916) in Japanese With Refr MM
Different stages of Multiple Myeloma - As per originally used Durie-Salmon staging system
NCT03836014: Phase 3: IFM 2018-Comparing Continuous Versus Fixed Duration Therapy DRd - RRMM Myeloma
NCT03859427: Phase 3: Once-weekly vs Twice-wkly Carfilzomib + Lenalidomide + Dex RRMM - A.R.R.O.W.2
NCT03839459: Phase 2: Denosumab for Smoldering Multiple Myeloma
Myeloma UK Publication, intended for UK Audience: Infopack for relapsed and/or refractory myeloma
NCT04184050: Phase 1/2: Dose Esc. & Dose Exp. of safety, Tolerability & PK of HPN217 in RRMM
NCT03975907: Phase 1/2 - Clinical Trial to Evaluate CT053 in Patients With RRMM (LUMMICAR STUDY 1)
NCT04162210: Phase 3 - Belantamab Mafodotin Vs Pomalidomide + Low-dose Dexamethasone (Pom/Dex) RRMM
NCT04113018: Phase 2: Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dex NDMM